Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Supervisory Board
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • ANKET®: Our NK cell engager Platform
    • Publications
  • Products
    • Pipeline overview
    • Clinical trials
    • ------------------
    • IPH6501
    • IPH6101
    • IPH6401
    • IPH62
    • IPH4502
    • Lacutamab
    • Monalizumab
    • IPH5201
    • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

ANKET® | Antibody-based NK cell Engager Therapeutics


Discover our proprietary platform

Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma


More about our lead asset

Harnessing the power of NK cells to develop therapeutic antibodies


Discover our cutting-edge science

Collaborating with a strong network to advance our pipeline


Discover our partnering opportunities

Previous Next

About Innate Pharma

#TheFutureIsInnate

Innate Pharma is a global clinical-stage oncology-focused biotech company. Our ambition is to establish innovative approaches to make a lasting difference to patients’ lives by providing drugs based on therapeutic antibodies that harness the immune system.

See company profile

Latest news

Innate Pharma announces first patient dosed in Phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors

January 27, 2025

Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York

January 21, 2025

Number of shares and voting rights of Innate Pharma as of December 31, 2024

January 16, 2025
See all press releases

Footer

  • Contact
  • Location
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

 +33 (0)4 30 30 30 30

 Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Supervisory Board
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • ANKET®: Our NK cell engager Platform
    • Publications
  • Products
    • Pipeline overview
    • Clinical trials
    • ------------------
    • IPH6501
    • IPH6101
    • IPH6401
    • IPH62
    • IPH4502
    • Lacutamab
    • Monalizumab
    • IPH5201
    • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers